• ARMGO Pharma Receives FDA Orphan Drug Designation for ARM210 americanpharmaceuticalreview
    September 07, 2018
    ARMGO Pharma announced the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to ARM210 (also known as S48168), a potential treatment for patients with Ryanodine Receptor Type 1 Related Myopathies (RYR1-RM).
PharmaSources Customer Service